1,5-anhydroglucitol has been researched along with canagliflozin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balis, DA; Meininger, G; Tong, C | 1 |
| Fortuna, D; McCloskey, LJ; Stickle, DF | 1 |
1 trial(s) available for 1,5-anhydroglucitol and canagliflozin
| Article | Year |
|---|---|
Effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol.
Topics: Blood Glucose; Canagliflozin; Deoxyglucose; Diabetes Mellitus, Type 2; Double-Blind Method; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
1 other study(ies) available for 1,5-anhydroglucitol and canagliflozin
| Article | Year |
|---|---|
Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol.
Topics: Canagliflozin; Deoxyglucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Models, Biological; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |